Race, insulin resistance and hepatic steatosis in chronic hepatitis C Potential conflict of interest: Dr. Zacks is on the speakers' bureau of Roche. He also received grants from Salix Pharmaceuticals.

Show simple item record

dc.contributor.author Conjeevaram, Hari S. en_US
dc.contributor.author Kleiner, David E. en_US
dc.contributor.author Everhart, Jay E. en_US
dc.contributor.author Hoofnagle, Jay H. en_US
dc.contributor.author Zacks, Steven en_US
dc.contributor.author Afdhal, Nezam H. en_US
dc.contributor.author Wahed, Abdus S. en_US
dc.date.accessioned 2007-09-20T17:55:22Z
dc.date.available 2008-04-03T18:45:01Z en_US
dc.date.issued 2007-01 en_US
dc.identifier.citation Conjeevaram, Hari S.; Kleiner, David E.; Everhart, Jay E.; Hoofnagle, Jay H.; Zacks, Steven; Afdhal, Nezam H.; Wahed, Abdus S. (2007). "Race, insulin resistance and hepatic steatosis in chronic hepatitis C Potential conflict of interest: Dr. Zacks is on the speakers' bureau of Roche. He also received grants from Salix Pharmaceuticals. ." Hepatology 45(1): 80-87. <http://hdl.handle.net/2027.42/55881> en_US
dc.identifier.issn 0270-9139 en_US
dc.identifier.issn 1527-3350 en_US
dc.identifier.uri http://hdl.handle.net/2027.42/55881
dc.identifier.uri http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17187406&dopt=citation en_US
dc.description.abstract Hepatic steatosis is common in chronic hepatitis C and has been linked to concurrent obesity, insulin resistance, diabetes, disease severity, and poor response to therapy. Racial differences in rates of obesity and diabetes may contribute to racial differences in hepatic steatosis and treatment response. The aim of the present study was to compare hepatic steatosis and its associations between African American (AA) and Caucasian American (CA) patients with chronic hepatitis C, genotype 1, participating in a prospective study of peginterferon and ribavirin therapy. Liver biopsy results were available from 194 AA patients and 205 CA patients. The 2 groups were compared for anthropometric, clinical, and biochemical features and insulin resistance estimated by the homeostasis model assessment index (HOMA-IR). Sixty-one percent of the AA patients and 65% of the CA patients had hepatic steatosis ( P = 0.38). In univariable analysis, steatosis was associated with HOMA-IR, body mass index, waist circumference, serum triglycerides, aminotransferase level, and histological scores for inflammation and fibrosis. After adjusting for these features, AA patients had a lower risk of steatosis than did CA patients (OR 0.54, 95% CI 0.32-0.91, P = 0.02). Insulin resistance but not steatosis was associated with a lower rate of sustained virological response when adjusted for known factors that predict response (relative risk 0.87, 95% CI 0.77-0.99, P = 0.028). Conclusion : After adjusting for the higher prevalence of features associated with hepatic steatosis, AA patients had a lower prevalence of hepatic steatosis than did CA patients with chronic hepatitis C, genotype 1. Insulin resistance but not steatosis was independently associated with lower sustained virological response. (H EPATOLOGY 2006;45:80–87.) en_US
dc.format.extent 150621 bytes
dc.format.extent 3118 bytes
dc.format.mimetype application/pdf
dc.format.mimetype text/plain
dc.publisher Wiley Subscription Services, Inc., A Wiley Company en_US
dc.subject.other Life and Medical Sciences en_US
dc.subject.other Hepatology en_US
dc.title Race, insulin resistance and hepatic steatosis in chronic hepatitis C Potential conflict of interest: Dr. Zacks is on the speakers' bureau of Roche. He also received grants from Salix Pharmaceuticals. en_US
dc.type Article en_US
dc.rights.robots IndexNoFollow en_US
dc.subject.hlbsecondlevel Internal Medicine and Specialties en_US
dc.subject.hlbtoplevel Health Sciences en_US
dc.description.peerreviewed Peer Reviewed en_US
dc.contributor.affiliationum University of Michigan, Ann Arbor, MI ; fax: (734) 936-7392 ; Division of Gastroenterology, University of Michigan, 3912 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0362 en_US
dc.contributor.affiliationother National Cancer Institute, National Institutes of Health, Bethesda, MD en_US
dc.contributor.affiliationother National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD en_US
dc.contributor.affiliationother National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD en_US
dc.contributor.affiliationother University of North Carolina at Chapel Hill, Chapel Hill, NC en_US
dc.contributor.affiliationother Beth Israel Deaconess Medical Center, Boston, MA en_US
dc.contributor.affiliationother University of Pittsburgh, Pittsburgh, PA en_US
dc.identifier.pmid 17187406 en_US
dc.description.bitstreamurl http://deepblue.lib.umich.edu/bitstream/2027.42/55881/1/21455_ftp.pdf en_US
dc.identifier.doi http://dx.doi.org/10.1002/hep.21455 en_US
dc.identifier.source Hepatology en_US
dc.owningcollname Interdisciplinary and Peer-Reviewed
 Show simple item record

This item appears in the following Collection(s)


Search Deep Blue

Advanced Search

Browse by

My Account

Information

Available Now


MLibrary logo